Supernus Pharmaceuticals (SUPN) Total Liabilities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Total Liabilities data on file, last reported at $423.9 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 33.9% year-over-year to $423.9 million in Q1 2026; TTM through Mar 2026 was $423.9 million, a 33.9% increase from a year earlier, with the FY2025 full-year figure at $390.9 million, up 17.63% from the prior year.
• Total Liabilities for Q1 2026 stood at $423.9 million, up from $390.9 million in the prior quarter.
• Over the last five years, Total Liabilities for SUPN reached as high as $879.7 million in Q1 2023 and fell as low as $316.6 million in Q1 2025.
• Historically, Total Liabilities has averaged $501.4 million across 5 years, with a median of $373.2 million in 2023.
• Across the five-year window, Total Liabilities slumped 57.38% in 2024 and jumped 33.9% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $816.3 million in 2022, then sank by 56.37% to $356.2 million in 2023, then declined by 6.69% to $332.3 million in 2024, then increased by 17.63% to $390.9 million in 2025, then rose by 8.44% to $423.9 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $423.9 million in Q1 2026, $390.9 million in Q4 2025, and $370.1 million in Q3 2025.